GLP-1 drugs, which include Ozempic and Wegovy, have become one of the most closely watched experimental approaches for slowing Alzheimer’s — a disease with few treatment options.
Alva Therapeutics, Inc. ("Alva") a company developing a novel oral incretin secretagogue based therapy for the treatment of Type 2 diabetes and obesity--announced that Mr. Jesper Høiland has been ...
The stock of telemedicine provider Hims & Hers has been under intense pressure, shedding approximately 38% of its value since ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback